Global Neuroscience Collaboration: Paul Thompson's Vision for AI in Brain Disease Research
Paul Thompson's recent lecture stresses global collaboration and ethical AI use in neuroscience.
Key Points
- • Dr. Paul M. Thompson highlights global collaboration in neuroscience.
- • ENIGMA consortium unites over 2,000 scientists from 47 countries.
- • AI tools promise better diagnostics while raising ethical concerns.
- • Calls for inclusive AI applications in diverse populations.
At the recent 2025 Organization for Human Brain Mapping (OHBM) annual meeting, Dr. Paul M. Thompson delivered the Talairach Lecture, advocating for enhanced global collaboration in neuroscience to combat brain diseases. He highlighted the role of the ENIGMA consortium, which he leads, comprising over 2,000 scientists from 47 countries, fostering an environment for worldwide data sharing and collaborative research.
Thompson emphasized that understanding brain diseases requires collective efforts, stating, "We’re entering a new era where our ability to tackle brain diseases is no longer limited by geography or scale." He showcased advanced AI models that can analyze brain MRI data, identify subtle patterns related to various conditions such as Alzheimer's and depression, and generate text summaries to assist clinicians. This innovation is set to boost diagnostic accuracy while expanding accessibility for healthcare professionals.
However, he also raised concerns regarding the ethical implementation of AI, particularly on issues of data privacy, fairness, and the need for resources in underrepresented communities. He urged the neuroscience community to adopt open-access platforms and inclusive diagnostic tools to ensure equitable benefits from AI advancements.
Arthur W. Toga, director of the USC Stevens INI, commended Thompson's insights, recognizing the urgent need for collaborative efforts in the global neuroscience community to improve diagnosis and treatment.